Associated Papers
Targeting ROR1 in combination with osimertinib in EGFR mutant lung cancer cells.
Nakagawa N et al.
Experimental Cell Research, 2021
Known and putative mechanisms of resistance to EGFR targeted therapies in NSCLC patients with EGFR mutations-a review.
Stewart EL et al.
Translational Lung Cancer Research, 2015
Select a paper to view details